MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- DIVI'S LABORATORIES LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Divis Laboratories Quarterly Results 
(DIVI)
Here are the latest quarterly results of Divis Laboratories. For more details, see the Divis Laboratories financial fact sheet and Divis Laboratories share price and chart. For a sector overview, read our pharmaceuticals sector report.
Divis Laboratories Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-17 |
3
Jun-17 |
3
Sep-17 |
3
Dec-17 |
3
Mar-18 |
3
Jun-18 |
3
Sep-18 |
3
Dec-18 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 10,667 | 8,212 | 8,902 | 10,379 | 10,880 | 9,953 | 12,850 | 13,429 | |
| Other income | Rs m | 209 | 297 | 336 | 170 | 482 | 488 | 801 | 346 | |
| Turnover | Rs m | 10,876 | 8,509 | 9,238 | 10,549 | 11,361 | 10,441 | 13,651 | 13,775 | |
| Expenses | Rs m | 7,047 | 5,764 | 6,130 | 7,117 | 7,015 | 6,435 | 7,709 | 8,196 | |
| Gross profit | Rs m | 3,620 | 2,448 | 2,772 | 3,261 | 3,865 | 3,519 | 5,141 | 5,233 | |
| Depreciation | Rs m | 314 | 323 | 339 | 374 | 388 | 416 | 424 | 425 | |
| Interest | Rs m | 10 | 5 | 8 | 3 | -2 | 6 | 2 | 25 | |
| Profit before tax | Rs m | 3,505 | 2,417 | 2,761 | 3,055 | 3,961 | 3,584 | 5,516 | 5,129 | |
| Tax | Rs m | 912 | 652 | 693 | 808 | 1,345 | 923 | 1,539 | 1,334 | |
| Profit after tax | Rs m | 2,593 | 1,765 | 2,068 | 2,247 | 2,616 | 2,662 | 3,977 | 3,795 | |
| Gross profit margin | % | 33.9 | 29.8 | 31.1 | 31.4 | 35.5 | 35.4 | 40.0 | 39.0 | |
| Effective tax rate | % | 26.0 | 27.0 | 25.1 | 26.5 | 33.9 | 25.7 | 27.9 | 26.0 | |
| Net profit margin | % | 24.3 | 21.5 | 23.2 | 21.6 | 24.0 | 26.7 | 30.9 | 28.3 | |
| Diluted EPS | Rs | 9.8 | 6.7 | 7.8 | 8.5 | 9.9 | 10.0 | 15.0 | 14.3 | |
| Diluted EPS (TTM) | Rs | 39.7 | 35.0 | 34.3 | 32.7 | 32.8 | 36.1 | 43.3 | 49.2 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Divis Laboratories 3QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: J.B.CHEMICALS GSK PHARMA CADILA HEALTHCARE ORCHID PHARMA LTD GLENMARK PHARMA
Compare DIVIS LABORATORIES With: J.B.CHEMICALS GSK PHARMA CADILA HEALTHCARE ORCHID PHARMA LTD GLENMARK PHARMA
Compare DIVIS LABORATORIES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
US China Trade War Escalations and Election Results: Volatility Set to Rule(Podcast)
India could be the latest direct victim of the US-China trade war. The increasing escalations have already slowed down global growth.
Views on news
DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)
Feb 4, 2019 | Updated on Feb 4, 2019For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
DIVIS LABORATORIES 2017-18 Annual Report Analysis (Annual Result Update)
Jan 1, 2019 | Updated on Jan 1, 2019Here's an analysis of the annual report of DIVIS LABORATORIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.
DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)
Nov 9, 2018 | Updated on Nov 9, 2018For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)
May 7, 2019The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...
Limited Upside, Higher Downside(The Honest Truth)
May 6, 2019The market's irrational reaction may present opportunities for a limited period of time.
3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)
May 10, 2019The one critical element that has made Amazon a force to reckon with...
A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)
May 9, 2019A filtered, neat list of high-dividend stocks with all this dirty work already done for you.
My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)
May 16, 2019Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
More|
| |
DIVIS LABORATORIES SHARE PRICE
May 17, 2019 (Close)
TRACK DIVIS LABORATORIES
- Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DIVIS LABORATORIES
DIVIS LABORATORIES - ADCOCK INGRAM COMPARISON
COMPARE DIVIS LABORATORIES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.